InstalabLoading...
InstalabLoading...
If you are being evaluated for a pelvic mass, tracking ovarian cancer treatment, or investigating unexplained pelvic symptoms, CA-125 (cancer antigen 125) is likely the first blood test that comes into play. It reflects what is happening on the internal surfaces of your body, especially in the pelvis. When a tumor grows, when inflammation flares, or when fluid collects where it should not, more of this protein enters your bloodstream.
What makes CA-125 both powerful and tricky is its lack of specificity. An elevated reading can mean ovarian cancer, but it can also mean endometriosis, heart failure, liver disease, or simply that you drew blood during your period. Understanding what this marker can and cannot tell you is the difference between useful information and unnecessary panic.
CA-125 is the name for fragments of a very large protein called MUC16, which belongs to a family of proteins called mucins. MUC16 sits on the outer surface of cells lining your ovaries, fallopian tubes, uterus, and the thin membranes that wrap around your abdominal and chest organs (called the peritoneum and pleura). When these cells are disturbed, whether by a growing tumor, inflammation, or the physical stretching caused by fluid accumulation, pieces of MUC16 break off and enter your blood.
The standard lab test detects these circulating fragments using a specific antibody. Think of CA-125 as a smoke alarm for your body's internal linings. It tells you something is activating those surfaces, but it does not tell you what. In a study of 380 hospitalized patients with elevated CA-125, causes ranged from liver cirrhosis and heart failure to lung disease and multiple cancer types, not only ovarian cancer.
This is the primary clinical reason CA-125 exists as a blood test. About 80 to 85% of women with advanced epithelial ovarian cancer have elevated levels, and roughly 50 to 63% of those with early-stage disease show an increase above the standard 35 U/mL threshold. When your doctor is evaluating a pelvic mass, an elevated CA-125 in a postmenopausal woman is considered highly suspicious and warrants referral to a gynecologic oncologist.
Beyond initial diagnosis, CA-125 is most valuable for tracking how well treatment is working. In a study of 350 women with high-risk early-stage ovarian cancer treated with platinum-based chemotherapy, those whose CA-125 normalized to 35 U/mL or below after the first chemotherapy cycle had substantially better outcomes: 81% were recurrence-free at five years, compared with 65% of those whose levels stayed elevated. Five-year survival was 87% versus 75%.
Researchers have refined this concept into a metric called KELIM, which models the speed at which CA-125 falls during early chemotherapy. KELIM reflects how sensitive a tumor is to treatment. In a large analysis of 5,884 patients across eight clinical trials, women with a favorable KELIM score (meaning their CA-125 dropped quickly) survived a median of 78.8 months, compared with 28.4 months for those with an unfavorable score. That translates to about half the risk of death (a hazard ratio of 0.46) after adjusting for cancer stage and surgical outcome.
The 35 U/mL threshold was developed in the 1980s using predominantly White female populations, and recent evidence shows this matters. In a national study of over 250,000 ovarian cancer cases, American Indian, Asian, and Black women were significantly less likely to have elevated CA-125 at diagnosis compared with White women, even within the same cancer stage. Women with a "false-negative" CA-125 (below 35 U/mL despite having cancer) experienced an average nine-day delay to starting chemotherapy.
If you are not White, a "normal" CA-125 should not be taken as fully reassuring when other signs point toward concern. Race-adjusted thresholds are being researched but are not yet clinically available.
CA-125 can serve as a non-invasive clue when endometriosis is suspected. A pooled analysis found that at a threshold of 30 U/mL or above, the test correctly identified about 93 out of 100 women without endometriosis (high specificity), but only caught about 52 out of 100 women who did have it (modest sensitivity). In moderate-to-severe disease, sensitivity improved to roughly 63%. This makes CA-125 useful for supporting a diagnosis you already suspect, but a normal result cannot rule endometriosis out.
CA-125 rises whenever the thin membranes lining your chest and abdomen are stretched or inflamed by fluid, which is exactly what happens in heart failure, liver cirrhosis, and other causes of effusions. A systematic review of six studies including 3,093 heart failure patients found that those with elevated CA-125 had roughly three times the risk of dying from any cause over about 20 months of follow-up (pooled relative risk of 3.29), and also faced more hospitalizations.
If your CA-125 is elevated but you have no gynecologic symptoms, your doctor should consider non-cancer causes, particularly heart failure, liver disease, or fluid collections in the chest or abdomen. In these settings, CA-125 tracks the severity of congestion rather than tumor burden.
In a study of 1,133 lung adenocarcinoma patients, elevated CA-125 was associated with worse progression-free survival, particularly in stage IV disease. CA-125 is not used to screen for lung cancer, but if you already have a diagnosis and your CA-125 is measured, a high value carries prognostic weight.
Nearly all guidelines and clinical studies use the same threshold for CA-125, though it was derived from a limited population and may not be equally sensitive across racial and ethnic groups. These ranges apply to immunoassay-based serum CA-125 tests, which is the standard method. Different lab platforms can produce slightly different numbers for the same sample, so always compare results from the same lab.
| Range | Level | What It Suggests |
|---|---|---|
| Below 35 U/mL | Within standard limits | Used as the conventional upper limit of normal across major guidelines (ACOG, NICE, international bodies). Does not guarantee the absence of disease. |
| 35 U/mL or above | Elevated | Warrants further evaluation. In postmenopausal women with a pelvic mass, this triggers gynecologic oncology referral. In premenopausal women, many benign causes are possible. |
| Below 22 U/mL | Lower threshold (research context) | In screening trials, using 22 U/mL instead of 35 U/mL detected about 67% of ovarian cancers versus 41% at the standard cutoff, at the cost of more false positives. |
Compare your results within the same lab over time. A single CA-125 value is far less informative than a trend.
CA-125 has substantial natural variation from one blood draw to the next, even in healthy women. Research on biological variability shows that the within-person coefficient of variation (a measure of how much a number bounces around) is approximately 35.5%. The practical consequence: a change between two serial results needs to be roughly 80 to 85% to be statistically meaningful. A result of 25 U/mL one month and 30 U/mL the next is well within normal noise.
Because of this variability, population-wide fixed cutoffs like 35 U/mL are blunt instruments. Your own personal baseline and trajectory are far more informative. Large screening trials have shown that risk algorithms using serial CA-125 readings over time (called ROCA, for risk of ovarian cancer algorithm) detect significantly more cancers than any single-threshold approach, improving sensitivity from roughly 41% to 87% at similar specificity.
If you are tracking CA-125 proactively, establish a baseline, then retest in 6 to 12 months. If you are monitoring a known condition or have risk factors, your clinician may recommend more frequent draws. The key is that a consistent, directional change across at least two to three measurements matters far more than any single number.
Given the ~35% biological variability, many factors can push a single reading into or out of the "elevated" zone without reflecting a meaningful change in your health.
Immune checkpoint inhibitor therapy for cancer can also cause early CA-125 rises that do not necessarily mean the cancer is progressing. In a study of 59 ovarian cancer patients on these drugs, most had CA-125 increases within 12 weeks regardless of whether the treatment was working. The size of the increase mattered: those benefiting from treatment saw a median rise of about 34%, while those not benefiting saw about 195%.
If your CA-125 comes back below 35 U/mL and you have no symptoms, that is reassuring but not a guarantee. About 12 to 24% of ovarian cancers present with a normal CA-125, and this fraction is higher in some racial and ethnic groups. If you have ongoing pelvic symptoms, a family history of ovarian cancer, or a known BRCA mutation, do not stop investigating based on a single normal CA-125.
If your result is elevated, the next step depends on context. For a postmenopausal woman with a pelvic mass, referral to a gynecologic oncologist is standard. For a premenopausal woman, the list of benign causes is long, and the most useful companion test is HE4 (human epididymis protein 4), which has higher specificity for distinguishing malignant from benign pelvic masses. Combining CA-125 with HE4 improves early-stage ovarian cancer detection from roughly 63% to about 81% at high specificity.
If you have no gynecologic explanation, consider whether heart failure, liver disease, or serosal fluid collections could be contributing. An NT-proBNP test (a heart failure marker) and basic liver function tests can help sort this out. For anyone with an unexplained elevated CA-125, retest in 4 to 8 weeks. A persistent or rising value warrants imaging, typically a transvaginal ultrasound. A value that normalizes on retest was likely driven by a transient cause.
Despite its value in monitoring known disease, CA-125 has not proven effective as a general population screen for ovarian cancer. Large trials in postmenopausal, average-risk women found that even sophisticated screening strategies using serial CA-125 with ultrasound could detect cancers at earlier stages but did not reduce deaths from the disease. The preclinical window for detecting high-grade serous ovarian cancer by CA-125 is only about 12 months, with tumor doubling times around 3 months, making annual screening inherently limited.
A randomized trial also showed that routine CA-125 surveillance after ovarian cancer treatment, compared with waiting for symptoms, led to more chemotherapy and worse quality of life without improving survival. This does not mean CA-125 is useless in follow-up. It means the decision about when to act on a rising CA-125 should be deliberate and shared between you and your oncologist, not reflexive.
For high-risk women, such as those with BRCA1 or BRCA2 mutations or strong family histories, CA-125 combined with transvaginal ultrasound is sometimes used for surveillance, though even in this group a clear mortality benefit has not been proven. If you carry a known genetic risk, establishing a CA-125 baseline and tracking your personal trend over time gives you data to work with as the science matures.
Evidence-backed interventions that affect your Cancer Antigen 125 level
Cancer Antigen 125 is best interpreted alongside these tests.